Enzyme catalyzed therapeutic compounds

Details Enzyme catalyzed therapeutic compounds Enzyme catalyzed therapeutic compounds

2003-10-07

2009-10-20

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S026800, C435S008000, C435S063000, C435S064000

Reexamination Certificate

active

07605144

ABSTRACT:
This invention provides novel compounds selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analogs. The compounds are useful to treat or prevent diseases such as cancer.

REFERENCES:
patent: 3852266 (1974-12-01), Kiyanagi et al.
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4267171 (1981-05-01), Bergstrom et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4668777 (1987-05-01), Caruthers et al.
patent: 4816570 (1989-03-01), Farquhar
patent: 4948882 (1990-08-01), Ruth
patent: 4963263 (1990-10-01), Kauver
patent: 4963533 (1990-10-01), De Clercq et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5070082 (1991-12-01), Murdock et al.
patent: 5077282 (1991-12-01), Murdock et al.
patent: 5077283 (1991-12-01), Murdock et al.
patent: 5085983 (1992-02-01), Scanlon
patent: 5116822 (1992-05-01), De Clercq et al.
patent: 5116827 (1992-05-01), Murdock et al.
patent: 5133866 (1992-07-01), Kauver
patent: 5137724 (1992-08-01), Balzarini et al.
patent: 5212161 (1993-05-01), Moriniere et al.
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5217869 (1993-06-01), Kauver
patent: 5233031 (1993-08-01), Borch et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5300425 (1994-04-01), Kauver
patent: 5338659 (1994-08-01), Kauver et al.
patent: 5430148 (1995-07-01), Webber et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5516631 (1996-05-01), Frisch
patent: 5521161 (1996-05-01), Malley et al.
patent: 5527900 (1996-06-01), Balzarini et al.
patent: 5596018 (1997-01-01), Baba et al.
patent: 5616564 (1997-04-01), Rapaport et al.
patent: 5627165 (1997-05-01), Glazier
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5663321 (1997-09-01), Gmeiner et al.
patent: 5733896 (1998-03-01), Holý et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5968910 (1999-10-01), Balzarini
patent: 5981507 (1999-11-01), Josephson et al.
patent: 6057305 (2000-05-01), Holý et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6339151 (2002-01-01), Shepard et al.
patent: 6495553 (2002-12-01), Shepard
patent: 6589941 (2003-07-01), Fahrig et al.
patent: 6599499 (2003-07-01), Rosen et al.
patent: 6677314 (2004-01-01), Klecker et al.
patent: 6677315 (2004-01-01), Klecker et al.
patent: 6682715 (2004-01-01), Klecker et al.
patent: 6683045 (2004-01-01), Klecker et al.
patent: 6683061 (2004-01-01), Shepard et al.
patent: 6703374 (2004-03-01), Klecker et al.
patent: 2001/0034440 (2001-10-01), Shepard et al.
patent: 2002/0147175 (2002-10-01), Shepard et al.
patent: 2002/0151519 (2002-10-01), Shepard et al.
patent: 32 29 169 (1984-02-01), None
patent: 0 311 107 (1989-04-01), None
patent: 0 311 108 (1989-04-01), None
patent: 0 316 592 (1989-05-01), None
patent: 982776 (1965-02-01), None
patent: 88451 (1986-01-01), None
patent: WO 89/05817 (1989-06-01), None
patent: WO 90/03978 (1990-04-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 92/19767 (1992-11-01), None
patent: WO 93/06120 (1993-04-01), None
patent: WO 94/03467 (1994-02-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 95/01806 (1995-01-01), None
patent: WO 95/08556 (1995-03-01), None
patent: WO 95/09865 (1995-04-01), None
patent: WO 95/12678 (1995-05-01), None
patent: WO 96/03151 (1996-02-01), None
patent: WO 96/07431 (1996-03-01), None
patent: WO 96/07413 (1996-04-01), None
patent: WO 96/10030 (1996-04-01), None
patent: WO 96/10300 (1996-04-01), None
patent: WO 96/23506 (1996-08-01), None
patent: WO 96/29336 (1996-09-01), None
patent: WO 96/33168 (1996-10-01), None
patent: WO 96/40088 (1996-12-01), None
patent: WO 96/40708 (1996-12-01), None
patent: WO 96/40739 (1996-12-01), None
patent: WO 97/25342 (1997-07-01), None
patent: WO 97/28179 (1997-08-01), None
patent: WO 97/49717 (1997-12-01), None
patent: WO 98/49177 (1998-11-01), None
patent: WO 99/06072 (1999-02-01), None
patent: WO 99/08110 (1999-02-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO 99/23104 (1999-05-01), None
patent: WO 99/37753 (1999-07-01), None
patent: WO 00/18755 (2000-04-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO 01/07088 (2001-02-01), None
patent: WO 01/07454 (2001-02-01), None
patent: WO 01/83501 (2001-11-01), None
patent: WO 01/85749 (2001-11-01), None
Hakimelahi et al., “Design, Synthesis, and Structure-Activity Relationship of Novel Dinucleotide Analogs as Agents Against Herpes and Human Immunodeficiency Viruses,”Journal of Medicinal Chemistry, 38(23), 4648-4659 (Nov. 10, 1995).
(RA) Barr et al., “Inhibition of Thymidylate Synthetase by 5-Alkynyl-2′-deoxyuridylates,” Journal of Medicinal Chemistry, 24(12), 1385-1388(1981).
(SA) Bergstrom et al., “Synthesis of (E)-5-(3,3,3-Trifluoro-1-propenyl)-2′-deoxyuridine and Related Analogues: Potent and Unusually Selective Antiviral Activity . . . ,” Journal of Medicinal Chemistry, 27(3), 279-284 (1984).
(TA) Bigge et al., “Palladium-Catalyzed Coupling Reactions of Uracil Nucleosides and Nucleotides,” J. American Chemical Society, 102(6), 2033-2038 (Mar. 12, 1980).
(UA) Cho et al., “(E)-5-(3-Oxopropen-1-yl)-2′-deoxyuridine and (E)-5-(Oxopropen-1-yl)-2i,3′-dideoxyuridine; New Antiviral Agents: Syntheses and Biological Activity,” Tetrahedron Letters, 35(8), 1149-1152 (1994).
(VA) Crisp, G. T., “Synthesis of 5-Alkenyl-2′-deoxyuridines via Organostannanes,” Synthetic Communications, 19(11&12), 2117-2123 (1989).
(WA) Fries et al., “Synthesis and Biological Evaluation of 5-Fluoro-2′-deoxyuridine Phosphoramidate Analogs,” Journal of Medicinal Chemistry, 38(14), 2672-2680 (1995).
(YA) Hobbs, F. W., Jr., “Palladium Catalyzed Synthesis of Alkynylamino Nucleosides. A Universal Linker for Nucleic Acids,” Journal of Organic Chemistry, 54(14), 3420-3422 (1989).
(ZA) Hsiao et al., “Synthesis of 5′-Thymidinyl Bis(1-aziridinyl)phosphonates as Antineoplastic Agents,” Journal of Medicinal Chemistry, 24(7), 887-889 (1981).
(RB) Krajewska et al., “Pyrimidine Ribonucleoside Phosphorylase Activity vs 5-and/or 6-Substituted Uracil and Uridine Analogues, Including Conformational Aspects,” Biochemical Pharmacology, 31(6), 1097-1102 (1982).
(SB) McIntee et al., “Probing the Mechanism of Action and Decomposition of Amino Acid Phosphoramidates of Antiviral Nucleoside Prodrugs,” Journal of Medicinal Chemistry, 40(21), 3323-3331 (1997); published in Advance ACS Abstracts, Sep. 15, 1997).
(TB) Robins et al. (I), “Nucleic Acid Related Compounds. 31. Smooth and Efficient Palladium-Copper Catalyzed Coupling of Terminal Alkynes with 5-lodouracil Nucleosides,” Tetrahedron Letters, 22, 421-424 (1981).
(UB) Robins et al. (II), “Nucleic Acid Related Compounds. 39. Efficient Conversion of 5-lodo to 5-Alkynyl and Derived 5-Substituted Uracil Bases and Nucleosides,” Journal of Organic Chemistry, 48(11), 1854-1862 (1983).
(VB) Ruth et al., “C-5 Substituted Pyrimidine Nucleosides. 1. Synthesis of C-5 Allyl, Propyl, and Propenyl Uracil and Cytosine Nucleosides via Organopalladium Intermediates,” Journal of Organic Chemistry, 43(14), 2870-2876 (1978).
(WB) Griengl et al., “Phosphonoformate and Phosphonoacetate Derivatives of 5-Substituted 2Ö-Deoxyuridines: Synthesis and Antiviral Activity,” Journal of Medicinal Chemistry, 31(9), 1831-1839 (1988).
(XB) Gonen et al., “Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Hetastatic Colorectal Cancer,” Journal of Clinical Oncology, 21(3), 406-412 (Feb. 1, 2003).
(YB) Rahman et al., “Elevated Levels of Thymidylate Synthase Linked to Cancer Etiology,” Cancer Cell, 5, 341-351 (2004); summarized in CCR/Frontiers in Science, 4, 6-7 (Mar. 2005).
Firestone et al., “A Comparison of the Effects of Antitumor Agents Upon Normal Human

Affiliated with

Also associated with

Rating

Enzyme catalyzed therapeutic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enzyme catalyzed therapeutic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme catalyzed therapeutic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128773